Pulmonary Arterial Hypertension News and Research

RSS
Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Meta-analysis supports combination therapy for PAH patients

Meta-analysis supports combination therapy for PAH patients

Minimally important dyspnoea, fatigue changes in PAH patients defined

Minimally important dyspnoea, fatigue changes in PAH patients defined

Increased BMP7 levels predict PAH mortality

Increased BMP7 levels predict PAH mortality

BMPR2 mutations affect outcomes of PAH patients

BMPR2 mutations affect outcomes of PAH patients

Tricuspid regurgitation tied to outcomes in PAH patients

Tricuspid regurgitation tied to outcomes in PAH patients

Regulatory immune cells compromised in PAH

Regulatory immune cells compromised in PAH

PAH role proposed for left heart failure biomarker

PAH role proposed for left heart failure biomarker

Left ventricular tissue phase mapping predicts PAH outcomes

Left ventricular tissue phase mapping predicts PAH outcomes

Ambrisentan avoids sildenafil drug interaction in PAH patients

Ambrisentan avoids sildenafil drug interaction in PAH patients

BMPR2 mutations affect outcomes of PAH patients

BMPR2 mutations affect outcomes of PAH patients

Arrhythmias worth treating in PAH patients

Arrhythmias worth treating in PAH patients

Selexipag reduces clinical events in PAH patients

Selexipag reduces clinical events in PAH patients

New blood biomarkers could lead to better evaluation of treatment for patients with PAH

New blood biomarkers could lead to better evaluation of treatment for patients with PAH

Selexipag holds promise for treatment of pulmonary hypertension

Selexipag holds promise for treatment of pulmonary hypertension

Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

RV glucose metabolism changes associated with RV function

RV glucose metabolism changes associated with RV function

Early promise for pulmonary artery denervation in PAH patients

Early promise for pulmonary artery denervation in PAH patients

Right atrial function could be prognostic in PAH

Right atrial function could be prognostic in PAH

Sildenafil drug improves insulin sensitivity in people at risk for diabetes

Sildenafil drug improves insulin sensitivity in people at risk for diabetes